Prior to leaving my position at the Children’s Hospital of Philadelphia Research Institute in early December 2016, I wrote the following stories which were later published in February and March 2017:
I wrote the following stories published in December 2016 and January 2017 by the Children’s Hospital of Philadelphia Research Institute:
CHOP Research In the News: Hypertension, Cancer Survivors’ Parents, Breastfeeding, Antibiotics, Allergies
I wrote (or edited, as noted) the following articles published in October 2016 by the Children’s Hospital of Philadelphia Research Institute:
I noticed a CHOP-affiliated co-author, Dr. Ganetzky, listed on a piece in the journal Academic Medicine calling for action on gender equality. I approached Dr. Ganetzky with the idea for a guest blog post on the subject and worked with her to refine and edit the post for publication.
CHOP Research In the News: Cancer Moonshot Yields Data-Sharing Initiatives, Hemophilia Surprise, Mitochondrial Medal
I wrote the following stories published by The Children’s Hospital of Philadelphia Research Institute in September 2016:
I wrote the following articles published by The Children’s Hospital of Philadelphia Research Institute in April 2016:
Originally published in Bench to Bedside, the CHOP Research monthly publication.
I prepared this article based on the project descriptions and email correspondence with the investigators.
Many cancer treatments have harmful side effects when they act on healthy tissues in addition to cancer cells. A team led by Garrett M. Brodeur, MD, director of the Cancer Predisposition Program at CHOP, and funded by a CURE grant, is seeking ways to increase drug delivery to the tumors to improve drugs’ effectiveness while reducing their toxicity.
Their method uses tiny nanoparticles as delivery vehicles. Nanoparticles are a promising way to get drugs into tumors because tumor blood vessels are leaky, and the nanoparticles can enter the tumor much more easily than normal tissues.
“By increasing drug delivery to tumors by one or two orders of magnitude, we can achieve dramatically better anti-tumor effects while simultaneously decreasing total drug exposure to patients,” Dr. Brodeur said.
Originally published on Cornerstone, the CHOP Research Blog.
I composed this original article based on an interview with the investigator.
Today at the White House, President Obama welcomed guests, including Adam Resnick, PhD, representing The Children’s Hospital of Philadelphia, for a morning of remarks and discussions about what the Precision Medicine Initiative (PMI) has achieved to date, and how it can take the next steps into the new era of medicine that delivers the right treatment at the right time to the right person. One way CHOP will be an integral part of that effort is through its commitment to data-driven discovery in pediatrics.
The PMI, which President Obama first announced in his 2015 State of the Union speech, launched last year with a White House event attended by CHOP leukemia patient Emily Whitehead and by the hospital’s then-CEO, Steven Altschuler, MD. The pair was invited in recognition of the progress at CHOP and the University of Pennsylvania in developing an investigational precision-medicine T-cell therapy for cancer patients like Emily.
But that type of discovery is only one part of the precision medicine equation, according to Dr. Resnick, co-director and co-founder of CHOP’s new Center for Data-Driven Discovery in Biomedicine (D3B).
“Even to make a new T-cell therapy, you have to begin with data about what to target,” Dr. Resnick said. “The other side of the coin in harnessing the potential of precision medicine is empowering the pediatric community to share and use data transparently and collaboratively through initiatives that connect patients, clinicians, and researchers to that data.”